Sysmex Co. (OTCMKTS:SSMXY) Short Interest Update

Sysmex Co. (OTCMKTS:SSMXYGet Free Report) was the recipient of a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 3,000 shares, a decrease of 25.0% from the February 13th total of 4,000 shares. Based on an average trading volume of 112,900 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s shares are short sold.

Sysmex Trading Up 2.0 %

SSMXY opened at $19.32 on Monday. Sysmex has a one year low of $14.38 and a one year high of $28.41. The stock has a market capitalization of $12.16 billion, a PE ratio of 35.86 and a beta of 0.88. The business’s 50 day moving average price is $18.47 and its 200 day moving average price is $19.10. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.42 and a current ratio of 3.19.

Sysmex (OTCMKTS:SSMXYGet Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.17 EPS for the quarter. As a group, equities research analysts expect that Sysmex will post 0.57 EPS for the current year.

Sysmex Company Profile

(Get Free Report)

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.

See Also

Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.